Natera, Inc. (Nasdaq: NTRA) has appointed Solomon Moshkevich as chief executive officer and a member of its board of directors, effective 5 November 2026, replacing Steve Chapman as the molecular diagnostics company enters another phase of commercial and international expansion. The leadership transition was announced alongside third-quarter financial results showing revenue growth of 34.1% to US$794 million and a 60.9% increase in oncology testing volumes.
Moshkevich, who joined Natera in 2011, previously served as president of clinical diagnostics and played a central role in developing and commercialising the company’s cell-free DNA testing portfolio. Chapman will remain a consultant and an adviser to the board, providing continuity as the new chief executive assumes responsibility for a business approaching US$3 billion in annual revenue.
The appointment comes during a period of substantial growth across Natera’s molecular residual disease testing business, supported by expanding clinical evidence, reimbursement arrangements and regulatory progress in multiple markets. However, the company continues to report GAAP operating losses, making the conversion of higher testing volumes into sustainable profitability a central consideration.
For Natera, the transition is less about replacing its existing commercial strategy than determining how rapidly its precision medicine platform can scale while maintaining laboratory performance, clinical credibility and financial discipline.
Why has Natera selected Solomon Moshkevich to succeed Steve Chapman?
Moshkevich has spent 15 years at Natera, holding responsibilities across product development, scientific affairs, clinical operations, international commercial activities, quality management and portfolio strategy.
His most recent position as president of clinical diagnostics gave him direct experience overseeing the company’s principal testing businesses and the infrastructure supporting their commercial development.
The breadth of his responsibilities distinguishes the appointment from a conventional external leadership recruitment. Natera has selected an executive closely associated with the development and expansion of its existing diagnostic portfolio.
Moshkevich previously served as the company’s first general manager of oncology, an increasingly important business as demand for circulating tumour DNA testing expands.
His experience also includes reproductive health, where Natera established its commercial position through noninvasive prenatal testing and related genetic screening services.
The appointment therefore provides leadership continuity across the company’s three principal areas of activity: oncology, women’s health and organ health.
Executive chairman and co-founder Matthew Rabinowitz indicated that Moshkevich’s long involvement in Natera’s development and his role in expanding the oncology business were important considerations in the succession.
Chapman similarly identified the incoming chief executive’s involvement in the company’s major strategic decisions as a foundation for continued execution.
The board has not announced a fundamental change in business direction. Instead, the succession appears designed to preserve the company’s existing strategic momentum while introducing a new phase of operational leadership.
However, continuity does not eliminate execution risk. As a diagnostics business expands, the requirements for laboratory capacity, regulatory compliance, payer relationships and customer support become increasingly demanding.
Moshkevich will need to manage these responsibilities while allocating resources across several businesses with different clinical and commercial characteristics.
What does Steve Chapman’s departure mean for Natera’s growth strategy?
Chapman’s tenure as chief executive coincided with a substantial expansion of Natera’s operations and financial scale.
The company said its revenue increased approximately tenfold during his leadership, reflecting the growth of its reproductive health business and subsequent expansion into oncology and organ health.
That transformation involved developing new tests, investing in clinical evidence and building the commercial infrastructure required to serve a larger customer base.
Signatera has become a particularly important part of that expansion. The tumour-informed circulating tumour DNA test is used in molecular residual disease assessment and other defined clinical settings, supported by an expanding body of research.
Natera has also developed Prospera, a donor-derived cell-free DNA testing platform used in organ transplant assessment, alongside its established Panorama prenatal screening business.
The company’s revenue expansion demonstrates growing demand for molecular diagnostics, although commercial success does not mean that every proposed clinical application has the same evidence base or regulatory status.
Chapman’s continued involvement as a consultant and board adviser may help preserve institutional knowledge during the transition.
However, the announcement does not identify a fixed end date for his advisory responsibilities or disclose the complete financial terms of the arrangement.
For investors, the succession creates a governance question concerning whether a long-serving internal executive can maintain the company’s growth trajectory while establishing greater operating leverage.
The board’s decision suggests confidence in the existing leadership team, but the effectiveness of the transition will ultimately be measured through financial and operational outcomes rather than the familiarity of the incoming chief executive.
Why is Natera’s 61% oncology testing growth the most important commercial development?
Natera processed approximately 339,500 oncology tests during the third quarter of 2026, compared with approximately 211,000 in the corresponding period of 2025.
That represents growth of 60.9%, substantially above the company’s overall testing volume increase of 22.3%.
The difference demonstrates that oncology is expanding more rapidly than the company’s combined diagnostic portfolio, making it an increasingly important contributor to future growth.
Natera also reported that clinical molecular residual disease oncology units increased by approximately 32,700 from the second quarter of 2026.
This sequential increase is particularly relevant because molecular residual disease testing can involve repeated assessment over time, depending on the clinical context and applicable testing protocols.
Unlike a diagnostic test performed once to establish a disease classification, longitudinal molecular monitoring may require multiple samples as clinicians assess residual disease or recurrence risk.
The resulting commercial model can create recurring testing demand, although actual frequency depends on the intended clinical use, reimbursement and physician decisions.
Natera’s commercial expansion is supported by increasing clinical interest in circulating tumour DNA as a source of information about disease status.
However, detecting circulating tumour DNA does not automatically establish the most appropriate treatment strategy for every patient.
A positive molecular residual disease result may identify an increased risk of recurrence or provide information relevant to treatment selection in a defined setting. The clinical significance depends on the disease, assay performance and supporting evidence.
Similarly, a negative result does not necessarily prove that no cancer cells remain.
For Natera, continued growth will require maintaining clinicians’ confidence in the tests while demonstrating that their use provides information capable of improving clinical management.
The company must also support increasing sample volumes through reliable laboratory operations and timely reporting.
Higher oncology volumes create a substantial commercial opportunity, but the corresponding demand for sequencing, bioinformatics and laboratory capacity makes operational efficiency increasingly important.
How do Natera’s third-quarter financial results support the leadership transition?
Natera generated US$794 million in third-quarter revenue, compared with US$592.2 million a year earlier.
The 34.1% increase reflected higher testing volumes and improvements in average selling prices, according to the company.
Total testing volumes reached approximately 1.09 million during the quarter, compared with approximately 894,000 in the prior-year period.
The company reported results on approximately 1.02 million tests, compared with approximately 833,000 a year earlier.
The distinction between tests processed and tests reported is important because the measures describe different operational stages. Natera’s financial performance depends not simply on the number of samples received but also on completed testing, reimbursement and revenue recognition.
Gross profit increased to US$513.5 million from US$384.4 million.
However, the GAAP gross margin declined slightly to 64.7% from 64.9%, despite the substantial increase in absolute gross profit.
The comparison was influenced by changes in revenue estimates associated with historical collections. Excluding those adjustments, Natera reported sequential improvement in its non-GAAP gross margin.
These accounting distinctions matter because improvements in recognised revenue and collection estimates can affect reported profitability independently of underlying laboratory processing efficiency.
Operating expenses increased to US$576.1 million from US$482 million, reflecting additional investment in personnel, clinical programmes and product development.
Despite that increase, the company’s operating loss narrowed to US$68.3 million from US$97.6 million.
The net loss also declined, reaching US$59.9 million compared with US$87.5 million in the third quarter of 2025.
This indicates that revenue growth is increasingly offsetting the company’s substantial operating expenditure, although Natera has not yet achieved consistent GAAP profitability.
The company ended September with approximately US$1.097 billion in cash, cash equivalents and restricted cash, providing financial resources for continued investment.
That amount should not be interpreted as unrestricted cash alone because it includes restricted balances.
The combination of rising revenue, narrowing losses and substantial liquidity provides Moshkevich with a stronger financial foundation for further expansion.
However, the company’s next phase will be judged partly on whether operating expenditure grows more slowly than revenue over time.
How does Signatera’s FDA approval change the regulatory outlook for Natera’s oncology business?
One of Natera’s most important regulatory developments in 2026 was the FDA’s approval of Signatera CDx on 15 May.
The approved test is a personalised, tumour-informed circulating tumour DNA assay designed to identify molecular residual disease through analysis of blood samples using information derived from a patient’s tumour.
The FDA approval is specifically linked to identifying molecular residual disease-positive patients with muscle-invasive bladder cancer who may benefit from treatment with atezolizumab products according to the approved therapeutic labelling.
This represents a companion diagnostic indication rather than broad FDA approval of Signatera for every cancer type or every proposed monitoring application.
The distinction is important because Natera’s wider Signatera testing business supports multiple clinical uses under different regulatory and reimbursement arrangements.
The approval establishes a specific authorised application in which molecular residual disease status is relevant to identifying patients who may benefit from a defined treatment.
It does not mean that clinicians can use the same regulatory approval to justify every proposed circulating tumour DNA-guided treatment decision.
Nor does a negative result establish that residual cancer is absent. The approved test must be interpreted according to its performance characteristics and intended use, alongside the patient’s broader clinical information.
For Natera, the regulatory milestone strengthens the clinical and commercial position of its technology in precision oncology.
Companion diagnostic approval can also support deeper relationships with pharmaceutical manufacturers developing therapies linked to molecular biomarkers.
However, future expansion into other treatment-selection indications may require additional evidence and regulatory submissions.
Moshkevich will therefore need to manage a business in which the commercial portfolio extends beyond the precise indications covered by individual FDA decisions.
Why are Japan and Europe becoming important expansion opportunities for Signatera?
Natera achieved additional international regulatory milestones during 2026.
In June, the company announced that Japan’s Pharmaceuticals and Medical Devices Agency had approved Signatera for molecular residual disease assessment in colorectal cancer within the specified adjuvant treatment setting.
Natera subsequently indicated that commercial availability in Japan was expected by the end of 2026, subject to final pricing and reimbursement arrangements.
The distinction between regulatory approval and reimbursement is important because a test may be authorised without immediately becoming commercially accessible under national healthcare payment systems.
In July, the company also announced that Signatera had received Class C certification under the European Union’s In Vitro Diagnostic Regulation.
The certification covers the relevant assay platform, specimen collection components and associated software within the certified scope.
These regulatory developments strengthen Natera’s ability to pursue international commercial opportunities, but adoption will still depend on local healthcare practices, reimbursement and laboratory implementation.
International expansion introduces additional operational considerations because testing may involve specimen collection across different healthcare systems, transportation logistics and the processing of samples in appropriately authorised facilities.
Clinical evidence generated in one population may also need to be considered in relation to the characteristics of patients treated in another region.
For Moshkevich, who previously held responsibility for international sales and business development, these issues are familiar elements of the company’s commercial strategy.
However, the opportunity is not simply to reproduce the United States business in other countries.
Each market may have different requirements concerning laboratory services, diagnostic evidence, healthcare funding and the clinical uses for which testing is supported.
Successful expansion will depend on adapting Natera’s commercial and operational model to those differences.
What role will Panorama, Prospera and Latitude play under the new chief executive?
Although oncology is growing rapidly, Natera’s wider portfolio remains important to its financial performance and long-term positioning.
Panorama is the company’s established noninvasive prenatal screening test, using cell-free DNA analysis to assess the risk of selected chromosomal conditions during pregnancy.
The test operates in a different clinical context from oncology molecular residual disease testing, with distinct requirements concerning counselling, interpretation and patient communication.
Prospera supports organ transplant assessment through donor-derived cell-free DNA analysis.
Its clinical applications involve evaluating molecular signals associated with transplanted organs, potentially providing information relevant to transplant monitoring.
However, donor-derived cell-free DNA findings must be interpreted within the relevant clinical context and should not automatically be treated as a standalone diagnosis of transplant rejection.
Natera is also developing newer testing approaches, including Latitude, a tissue-free molecular residual disease assay investigated in colorectal cancer.
A peer-reviewed validation study published in January 2026 reported findings from 1,230 timepoints involving 195 colorectal cancer patients.
The study supports further evaluation and reimbursement efforts, but research validation and the commercial or regulatory status of a diagnostic test must remain distinct.
The company’s portfolio strategy creates opportunities to use scientific, computational and operational capabilities across several diagnostic markets.
However, each programme must demonstrate analytical performance, clinical validity and clinical utility appropriate to its intended purpose.
Moshkevich’s experience across the company’s existing businesses may support coordination of these investments.
The commercial challenge will be allocating resources between mature products generating established revenue and newer technologies requiring further clinical and regulatory work.
Why will reimbursement and laboratory economics determine Natera’s next profitability milestone?
Natera’s molecular diagnostics business depends on the interaction of testing demand, laboratory processing costs and reimbursement.
The company can increase testing volumes substantially without generating proportional revenue if reimbursement rates decline, collections deteriorate or the mix of tests changes.
Conversely, improving average selling prices and lowering processing costs can support margin expansion even when unit growth is more moderate.
The third-quarter results demonstrate both the opportunity and the complexity.
Revenue increased 34.1%, exceeding the 22.3% growth in total processed tests. The company attributed the difference partly to improvements in average selling prices.
However, the reported gross margin remained broadly flat year on year, reflecting the influence of collection estimate adjustments and other financial factors.
For Moshkevich, improving operating leverage will require continued attention to laboratory automation, sample processing efficiency, customer service and the economics of reimbursement.
Oncology testing may create attractive long-term opportunities because certain clinical applications involve serial monitoring.
However, payer coverage often applies only to defined diseases, treatment settings or testing frequencies.
A coverage determination for one application should not be interpreted as universal reimbursement for every use of the same technology.
Natera must also maintain appropriate laboratory quality systems as testing volumes increase.
The company operates laboratories certified under the Clinical Laboratory Improvement Amendments and accredited by the College of American Pathologists, alongside relevant quality management certifications.
Maintaining those standards is essential as the business expands across different diagnostic categories and jurisdictions.
The financial test is whether higher volumes and improved collections can eventually produce operating profitability without compromising analytical quality or clinical service.
How are Natera investors responding to the CEO transition and latest results?
Natera shares closed at US$363.76 on 5 November 2026, declining 6.97% from the previous closing price of US$391.03.
The shares had closed at US$414.30 on 30 October, meaning the stock declined approximately 12.2% over the subsequent trading sessions through 5 November.
The company’s reported 52-week trading range was US$181.00 to US$437.41, with an equity market capitalisation of approximately US$52.4 billion at the 5 November close.
The stock’s performance reflects significant investor expectations concerning Natera’s future growth, particularly in oncology diagnostics.
However, the leadership transition and third-quarter financial results were announced after the regular market close on 5 November.
Consequently, the 6.97% decline during that session cannot be attributed to the newly released CEO announcement or earnings report.
Subsequent trading may reflect investor interpretation of both developments, but it would be inappropriate to assign any movement exclusively to the succession without stronger evidence.
The company’s valuation is substantial relative to current annual revenue, indicating that investors are pricing in continued expansion and future improvements in profitability.
That creates sensitivity to changes in testing growth, gross margins, reimbursement assumptions and operating expenditure.
The appointment of a long-serving executive may reduce some uncertainty associated with leadership succession, but it does not eliminate the risks involved in meeting ambitious growth expectations.
Natera’s ability to sustain investor confidence will depend on whether the commercial performance of its diagnostic portfolio supports the company’s valuation over time.
What must Solomon Moshkevich deliver during Natera’s next phase of expansion?
Natera raised its full-year 2026 revenue guidance following the third-quarter results.
The company now expects revenue of US$3.005 billion to US$3.035 billion, compared with its previous range of US$2.85 billion to US$2.91 billion.
The increase of US$140 million at the midpoint provides a near-term measure of management’s confidence in continued testing demand and revenue performance.
Natera also expects full-year gross margin of approximately 64% to 66% and positive cash flow.
These targets establish a financial foundation for evaluating the incoming chief executive’s performance.
However, sustaining growth at the current pace will become increasingly demanding as the company’s revenue base expands.
The company will need to maintain strong oncology testing growth while continuing to develop evidence supporting broader clinical adoption.
International expansion will also require progress in reimbursement and operational implementation, particularly in markets where new regulatory authorisations have been secured.
At the same time, Natera must manage its established reproductive health business and invest selectively in organ health and newer diagnostic technologies.
Moshkevich has indicated that the company intends to extract more diagnostic information from clinical samples, extend its technologies into additional patient populations and improve integration with care delivery.
These objectives could create opportunities for new products and clinical applications, but they remain strategic intentions rather than confirmed future revenue.
The transition from Steve Chapman to Solomon Moshkevich therefore takes place at a commercially significant moment.
Natera has established a large molecular diagnostics business supported by rapid oncology growth, expanded regulatory recognition and increasing testing volumes.
Its next challenge is to demonstrate that the same platform can deliver sustainable profitability while supporting wider clinical use.
For Moshkevich, the decisive evidence will emerge through continued molecular residual disease testing adoption, successful international commercialisation, stronger laboratory economics and the ability to maintain clinical and regulatory credibility as Natera expands beyond its current scale.
Do you like this personality?
